Abstract
Introduction: Acute Myeloid Leukemia (AML) is a rare form of cancer characterized by the infiltration of abnormal white blood cells that accumulate in the bone marrow at a rapid rate. AML has an overall incidence of 4 per 100,000 persons and accounted for over 10,000 deaths within the United States in 2015 [1]. Indeed, AML also represents a disease typically associated with the elderly, as the median age of diagnosis for AML is around 72 years old [2].
Advances: Over the past decades we have seen major advances in terms of understanding AML’s biology and prognosis, but some questions still remain unanswered, particularly for the elderly population. This gap in our understanding of AML translates into unmet needs for this population. Conclusion: The current paper seeks to describe these specific needs and their associated barriers related to treatment, prognostic factors and relapse, health-related quality of life, disease costs, and palliative care support. Acquiring a better understanding of AML for elderly patients can lead to improved therapy options and quality-of-life for this population.Keywords: Acute myeloid leukemia, age, chemotherapy, treatment, unmet needs, older.
Current Cancer Therapy Reviews
Title:Understanding Unmet Needs in the Older Acute Myeloid Leukemia (AML) Patient
Volume: 12 Issue: 4
Author(s): Pablo Loarte, Irina Dashkova, Leanne Tortez*, Anna Dashkova, Andrzej Kozikowski, Ramy Ibrahim and Renee Pekmezaris
Affiliation:
- 175 Community Drive, 2nd Floor # 241C, Great Neck, NY 11021,United States
Keywords: Acute myeloid leukemia, age, chemotherapy, treatment, unmet needs, older.
Abstract: Introduction: Acute Myeloid Leukemia (AML) is a rare form of cancer characterized by the infiltration of abnormal white blood cells that accumulate in the bone marrow at a rapid rate. AML has an overall incidence of 4 per 100,000 persons and accounted for over 10,000 deaths within the United States in 2015 [1]. Indeed, AML also represents a disease typically associated with the elderly, as the median age of diagnosis for AML is around 72 years old [2].
Advances: Over the past decades we have seen major advances in terms of understanding AML’s biology and prognosis, but some questions still remain unanswered, particularly for the elderly population. This gap in our understanding of AML translates into unmet needs for this population. Conclusion: The current paper seeks to describe these specific needs and their associated barriers related to treatment, prognostic factors and relapse, health-related quality of life, disease costs, and palliative care support. Acquiring a better understanding of AML for elderly patients can lead to improved therapy options and quality-of-life for this population.Export Options
About this article
Cite this article as:
Loarte Pablo , Dashkova Irina, Tortez Leanne*, Dashkova Anna , Kozikowski Andrzej , Ibrahim Ramy and Pekmezaris Renee, Understanding Unmet Needs in the Older Acute Myeloid Leukemia (AML) Patient, Current Cancer Therapy Reviews 2016; 12 (4) . https://dx.doi.org/10.2174/1573394713666170323153716
DOI https://dx.doi.org/10.2174/1573394713666170323153716 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore the cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the ...read more
Current progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
Current Genomics Cytochrome P450 Gene Polymorphism and Cancer
Current Drug Metabolism The Expanding Role of Tumor Necrosis Factor-α Inhibitors in the Management of Rheumatic Diseases
Medicinal Chemistry Reviews - Online (Discontinued) Approaches Towards Better Immunosuppressive Agents
Current Topics in Medicinal Chemistry Lumiflavin Enhances the Effects of Ionising Radiation on Ovarian Cancer Stem-Like Cells by Inhibiting Autophagy
Anti-Cancer Agents in Medicinal Chemistry Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Signaling in Human B-Lymphoma Rafts
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Aberrant Regulation of Translation Initiation in Tumorigenesis
Current Molecular Medicine Synthesis, Characterization and Evaluation of Cytotoxicity of New Aminophosphonic Acid Diesters in Human Leukemia Cells
Letters in Drug Design & Discovery Combination Treatment of p53-Null HL-60 cells with Histone Deacetylase Inhibitors and Chlorambucil Augments Apoptosis and Increases BCL6 and p21 Gene Expression
Current Molecular Pharmacology Myelodysplastic/Myeloproliferative Neoplasms
Current Cancer Therapy Reviews Design, Synthesis and Anticancer Activity Against the MCF-7 Cell Line of Benzo-Fused 1,4-Dihetero Seven- and Six-Membered Tethered Pyrimidines and Purines
Current Medicinal Chemistry Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals Disseminated Intravascular Coagulation in Leukemia and Sepsis
Vascular Disease Prevention (Discontinued) Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents
Letters in Drug Design & Discovery The Use of Naphthoquinones and Furano-naphthoquinones as Antiinvasive Agents
Current Medicinal Chemistry The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews